Pharmacogenetics of Antidepressant-Induced Disinhibition

Recruiting now

Conditions studied: Obsessive-Compulsive Disorder, Anxiety Disorders, Major Depressive Disorder, Antidepressant Drug Adverse Reaction

In brief

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Key facts

Study ID

NCT03953014

Run by

University of Calgary

People needed

120

Starts

2019-01-02

Expected to finish

2026-12-30

Last updated by the study team

2026-05-14

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 6 - 24 years
• Medical records available
• Diagnosis of MDD, anxiety disorder, or OCD
• Current or past history of SSRI therapy

You may not qualify if…

• Inability of parent/legal guardian to give informed consent
• Inability of the child to give informed assent
• Unwillingness of child to provide saliva sample for genetic analysis
• Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.

Where it is running

• Child and Adolescent Addiction, Mental Health & Psychiatry — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.